Skip to main content

Table 3 Adjusted odds ratio of cytokines for prediction of persistent CE

From: Systemic inflammatory markers of persistent cerebral edema after aneurysmal subarachnoid hemorrhage

Variables

Univariable

Multivariablea

Multivariableb

OR

95% CI

p value

OR

95% CI

p value

OR

95% CI

p value

Eotaxin

 Eotaxin (T1), per 1 pg/mL increase

1.011

0.999–1.023

0.084

1.016

1.002–1.030

0.029

1.011

0.996–1.026

0.137

 Eotaxin (T2), per 1 pg/mL increase

1.002

0.987–1.016

0.815

N/A

     

 Eotaxin (T3), per 1 pg/mL increase

1.009

0.996–1.022

0.169

1.013

0.998–1.023

0.080

1.012

0.995–1.029

0.169

 Eotaxin (T4), per 1 pg/mL increase

1.009

1.00–1.018

0.063

1.012

1.001–1.023

0.030

1.019

1.002–1.035

0.024

GCSF

 GCSF (T1), per 1 pg/mL increase

1.003

0.999–1.008

0.172

1.004

0.999–1.009

0.157

1.003

0.997–1.009

0.280

 GCSF (T2), per 1 pg/mL increase

0.995

0.985–1.006

0.386

N/A

     

 GCSF (T3), per 1 pg/mL increase

1.004

0.988–1.010

0.154

1.015

1.000–1.030

0.054

1.013

0.994–1.031

0.175

 GCSF (T4), per 1 pg/mL increase

1.007

1.000–1.014

0.064

1.009

0.996–1.022

0.186

1.007

0.922–1.022

0.366

IL-10

 IL-10 (T1), per 1 pg/mL increase

1.003

0.999–1.007

0.168

1.005

0.999–1.011

0.076

1.003

0.996–1.011

0.350

 IL-10 (T2), per 1 pg/mL increase

0.994

0.974–1.014

0.525

N/A

     

 IL-10 (T3), per 1 pg/mL increase

1.006

0.968–1.046

0.757

N/A

     

 IL-10 (T4), per 1 pg/mL increase

1.004

0.993–1.014

0.499

N/A

     

PDGF-AA

 PDGF-AA (T1), per 10 pg/mL increase

1.001

1.000–1.001

0.216

N/A

     

 PDGF-AA (T2), per 10 pg/mL increase

0.998

0.996–1.001

0.214

N/A

     

 PDGF-AA (T3), per 10 pg/mL increase

1.000

0.999–1.001

0.849

N/A

     

 PDGF-AA (T4), per 10 pg/mL increase

1.000

1.000–1.001

0.143

1.005

1.000–1.011

0.072

1.006

0.999–1.014

0.075

sCD40L

 sCD40L (T1), per 10 pg/mL increase

0.998

0.992–1.003

0.419

N/A

     

 sCD40L (T2), per 10 pg/mL increase

0.993

0.983–1.003

0.173

N/A

     

 sCD40L (T3), per 10 pg/mL increase

0.998

0.995–1.001

0.281

N/A

     

 sCD40L (T4), per 10 pg/mL increase

1.000

1.000–1.000

0.060

1.003

1.001–1.006

0.016

1.003

1.000–1.006

0.053

IL1Ra

 IL1Ra (T1), per 1 pg/mL increase

1.001

1.000–1.003

0.102

1.002

1.000–1.004

0.103

1.000

0.998–1.003

0.814

 IL1Ra (T2), per 1 pg/mL increase

1.001

0.997–1.005

0.531

N/A

     

 IL1Ra (T3), per 1 pg/mL increase

1.002

0.999–1.004

0.144

1.002

1.000–1.005

0.071

1.001

0.998–1.004

0.497

 IL1Ra (T4), per 1 pg/mL increase

1.000

0.996–1.003

0.917

N/A

     

IL-6

 IL-6 (T1), per 1 pg/mL increase

1.014

1.005–1.023

0.003

1.015

1.004–1.026

0.006

1.008

0.996–1.021

0.200

 IL-6 (T2), per 1 pg/mL increase

1.002

0.990–1.015

0.696

N/A

     

 IL-6 (T3), per 1 pg/mL increase

1.014

1.002–1.026

0.024

1.018

1.002–1.034

0.025

1.009

0.991–1.027

0.331

 IL-6 (T4), per 1 pg/mL increase

1.002

0.996–1.008

0.535

N/A

     

IL-8

 IL-8 (T1), per 1 pg/mL increase

1.018

1.000–1.037

0.047

1.015

0.995–0.948

0.135

1.013

0.990–1.036

0.276

 IL-8 (T2), per 1 pg/mL increase

1.018

0.992–1.045

0.177

1.017

0.988–1.047

0.255

1.007

0.972–1.043

0.695

 IL-8 (T3), per 1 pg/mL increase

1.002

0.999–1.005

0.221

N/A

     

 IL-8 (T4), per 1 pg/mL increase

1.010

0.987–1.034

0.398

N/A

     

MCP-1

 MCP-1 (T1), per 1 pg/mL increase

1.001

0.999–1.003

0.220

N/A

     

 MCP-1 (T2), per 1 pg/mL increase

1.001

0.997–1.005

0.723

N/A

     

 MCP-1 (T3), per 1 pg/mL increase

1.001

1.000–1.003

0.142

1.001

0.999–1.003

0.181

1.000

0.998–1.002

0.741

 MCP-1 (T4), per 1 pg/mL increase

1.002

1.000–1.004

0.034

1.002

1.000–1.005

0.077

1.002

0.999–1.004

0.171

MIP1a

 MIP1a (T1), per 1 pg/mL increase

0.996

0.939–1.056

0.893

N/A

     

MIP1a (T2), per 1 pg/mL increase

1.000

0.940–1.063

0.992

N/A

     

 MIP1a (T3), per 1 pg/mL increase

1.013

0.983–1.044

0.393

N/A

     

 MIP1a (T4), per 1 pg/mL increase

0.967

0.874–1.071

0.522

N/A

     

RANTES

 RANTES (T1), per 1 pg/mL increase

1.000

1.000–1.001

0.733

N/A

     

 RANTES (T2), per 1 pg/mL increase

1.000

0.999–1.001

0.591

N/A

     

 RANTES (T3), per 1 pg/mL increase

1.000

1.000–1.001

0.240

N/A

     

 RANTES (T4), per 1 pg/mL increase

1.000

0.999–1.001

0.983

N/A

     

TNF-α

 TNF-α (T1), per 1 pg/mL increase

1.014

0.951–1.082

0.672

N/A

     

 TNF-α (T2), per 1 pg/mL increase

0.942

0.841–1.055

0.304

N/A

     

 TNF-α (T3), per 1 pg/mL increase

1.010

0.952–1.072

0.740

N/A

     

 TNF-α (T4), per 1 pg/mL increase

1.081

1.081–1.155

0.022

1.117

1.027–1.214

0.010

1.096

0.999–1.202

0.053

  1. CE cerebral edema, CI confidence interval, OR odds ratio, SAH subarachnoid hemorrhage
  2. aAdjustments were made for age, gender, race, risk factors and comorbidities in Table 1
  3. bAdjustments were made for age, gender, race, risk factors, comorbidities, clinical and radiographic severity of SAH and therapeutic intervention in Table 1